Adenosine Type A2A Receptor in Peripheral Cell from Patients with Alzheimer&apos;s Disease, Vascular Dementia, and Idiopathic Normal Pressure Hydrocephalus : A&#160;New/Old Potential Target by B. Arosio et al.
Un
co
rre
cte
d A
uth
or
 P
ro
of
Journal of Alzheimer’s Disease xx (20xx) x–xx
DOI 10.3233/JAD-160324
IOS Press
1
Review1
Adenosine Type A2A Receptor in Peripheral
Cell from Patients with Alzheimer’s
Disease, Vascular Dementia, and Idiopathic
Normal Pressure Hydrocephalus:
A New/Old Potential Target
2
3
4
5
6
Beatrice Arosioa,b,∗, Martina Casatia,c, Cristina Gussagoa, Evelyn Ferria,c, Carlo Abbateb,
Valeria Scortichinib, Elena Colomboa, Paolo Dionigi Rossib and Daniela Maria,b
7
8
aGeriatric Unit, Department of Medical Sciences and Community Health, University of Milan, Milan, Italy9
bFondazione Ca’ Granda, IRCCS Ospedale Maggiore Policlinico, Milan, Italy10
cNutritional Sciences, University of Milan, Milan, Italy11
Handling Associate Editor: Patrizia Mecocci12
Accepted 9 June 2016
Abstract. As the European population gets older, the incidence of neurological disorders increases with significant impact
on social costs. Despite differences in disease etiology, several brain disorders in the elderly (e.g., Alzheimer’s disease,
vascular dementia, normal pressure hydrocephalus) share dementia as a common clinical feature. The current treatment for
the majority of these diseases is merely symptomatic and does not modify the course of the illness. Symptoms of normal
pressure hydrocephalus are the only ones that can be modified if they are recognized in time and treated appropriately.
Therefore, an important clinical strategy may be disclosed by pathogenic pathways that can be modified and to find drugs
that can slow down or even arrest disease progression. Possibly a way to answer this question could be by re-examining all
the molecules which have so far succeeded in improving many aspects of cognitive deterioration in some neurodegenerative
conditions, that were not considered because of controversial opinions. The main purpose of this summary is to further
substantiate the hypothesis that the pathway of adenosine type A2A receptor could be used as a potential target to develop
new/old therapeutic strategies.
13
14
15
16
17
18
19
20
21
22
23
Keywords: Adenosine, adenosine receptors, elderly, neurodegeneration24
∗Correspondence to: Beatrice Arosio, Geriatric Unit, Depart-
ment of Medical Sciences and Community health, University of
Milan, Via Pace 9, 20122 Milan, Italy. Tel.: +39 02 55035405; Fax:
+39 02 50320735; E-mail: beatrice.arosio@unimi.it.
Up to one billion people worldwide suffer from 25
brain diseases, which include neurological disorders. 26
In Europe, brain disease represents 35% of all dis- 27
eases affecting 179 million patients and costing more 28
than 800 billion euro per annum, which is more 29
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cardiovascular disease and cancer combined [1]. As30
the European population gets older, the incidence31
of neurological disorders increases creating an enor-32
mous problem for social costs. Despite differences in33
disease etiology, several brain disorders in the elderly34
[e.g., Alzheimer’s disease (AD), vascular dementia35
(VaD), normal pressure hydrocephalus (NPH)] share36
dementia as common clinical symptom [2]. This leads37
us to believe that there could be a common patholog-38
ical pathway in different brain diseases.39
The current treatment for the majority of these dis-40
eases is merely symptomatic and does not modify41
the course of the illness. NPH symptoms are the only42
ones that we can modify if they are recognized in time43
and treated appropriately [3].44
Therefore, it is crucial to find pathogenic pathways45
that can be modified and to be able to test drugs that46
can slow down or even arrest disease progression.47
Possibly a way to answer this question could be48
by re-examining all the molecules which have so far49
succeeded in improving many aspects of cognitive50
deterioration in some neuropathological conditions51
that were not considered because of controversial52
opinions.53
ADENOSINE54
Many epidemiological studies showed that the55
usual consumption of moderate quantities of caffeine56
produces long-lasting benefits to memory function in57
healthy brains [4]. Such benefits include the reduc-58
tion of both memory decline caused by aging and the59
risk of developing dementia and AD, suggesting a60
potential therapeutic use of caffeine. But where do61
the beneficial effects of caffeine come from?62
Currently, the beneficial effects triggered on the63
brain by methylxanthine caffeine (1,3,7-trime-64
thylxanthine) seems to be related to structural65
similarities between the compound itself and an66
endogenously produced molecule known as adeno-67
sine.68
ATP (adenosine triphosphate) is not only the prin-69
cipal and universal cellular energetic compound, but70
it can also be released into the extracellular medium71
where it acts as a signaling molecule [5]. Almost72
every synaptic and secretory vesicle contains ATP,73
which can be stored with other classic neurotransmit-74
ters such as GABA or glutamate, or alone in ATP-only75
vesicles. ATP levels are usually very low in extra-76
cellular medium, but they rapidly increase during77
pathological conditions such as inflammation or cell78
death. ATP can act as either sole transmitter or as 79
co-transmitter. 80
ATP can be released from neurons and glial cells in 81
an uncontrolled manner or via vesicular release. After 82
its release, ATP is rapidly degraded into adenosine 83
5’-diphosphate (ADP), adenosine 5’-monophosphate 84
(AMP), and adenosine (Ado) [5, 6]. 85
ADENOSINE RECEPTORS 86
The physiological responses to Ado take place 87
through the binding and the activation of one or 88
more of the trans-membrane high-affinity A1 (A1R) 89
or A2A (A2AR), low-affinity A2B, or low-abundance 90
A3 receptors [7]. 91
These G-protein coupled receptors regulate the 92
second messenger cAMP in opposite directions; 93
while A1 and A3 receptors are inhibitory Gi-coupled, 94
A2A and A2B receptors are excitatory Gs-coupled, 95
thereby decreasing and increasing cAMP levels, 96
respectively [8, 9]. The activation of these recep- 97
tors can also modulate Ca2+ channels and the 98
phospholipase C pathway. 99
Through these actions and by modulating both the 100
release and the uptake of different neurotransmit- 101
ters, the balance between the activation of adenosine 102
A1R and A2AR allows the fine-tuning of synap- 103
tic transmission and plasticity in the hippocampus 104
[9]. 105
In particular, we can find A2AR in a wide vari- 106
ety of tissues, including the nervous system and the 107
peripheral immune system, where they are expressed 108
at different levels: from significantly high levels in 109
neurons and peripheral cells (lymphocytes and neu- 110
trophils) to lower levels in glial cells [7]. 111
The different levels of expression of A2AR in dif- 112
ferent tissues are consistent with the sophisticated, 113
multifaceted neurochemical, and molecular effects of 114
the Ado system. On the basis of in vitro [10, 11] 115
and in vivo [12] studies, it has become clear that 116
A2AR, through complex mechanisms which are still 117
poorly understood [13–15], plays a critical role in the 118
modulation of inflammatory reactions, influencing 119
functional outcome in a wide spectrum of pathologies 120
including brain diseases [16, 17]. 121
Considering data of gene expression and receptor 122
densities obtained by our group [18–20], the main 123
purpose of this summary is to further substantiate the 124
hypothesis that the pathway of A2AR could be used to 125
help stratify elderly patients and as a potential target 126
to develop new/old therapeutic strategies. 127
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A2AR in brain diseases128
A2AR could play a key role in different patholog-129
ical conditions; in particular we decided to focus on130
AD, VaD, and idiopathic NPH (iNPH) because these131
are the most frequently encountered in our clinical132
practice.133
a) Alzheimer’s disease134
Alzheimer’s disease (AD) is the most common age135
related progressive neurodegenerative disorder and136
the primary cause of dementia in the elderly [21].137
The characteristic clinical presentation of AD is138
a progressive loss of memory and specific cognitive139
function, ultimately leading to the loss of indepen-140
dence and death. The hallmark neuropathological141
changes in AD are neuritic plaques (amyloid-142
(A) deposition), neurofibrillary tangles (tauopa-143
thy), and neuronal loss most prominent in specific144
temporal, parietal, and frontal regions of the brain.145
Numerous studies support the hypothesis that AD146
pathology is more complex than A and tau147
accumulation, indicating the involvement of inflam-148
mation [22, 23], prionopathy [24], oxidative stress149
[25], and metabolic abnormalities [26, 27] in the150
brain.151
The blockade of adenosine A2AR affords neuro-152
protection against chronic noxious brain insults [28].153
It was also recently shown that A2A receptor antag-154
onists can prevent memory impairment in animal155
models of aging [29] and AD [30, 31].156
Indeed, several longitudinal studies support the157
inverse relationship between caffeine consumption158
and both decreased memory impairment associated159
with aging [32] as well as reduced risk of developing160
AD [33, 34] and generally dementia [35], showing161
also an improvement in psychomotor speed and ver-162
bal memory performance in non demented elderly163
population [36, 37], less decline in verbal retrieval164
and visuospatial memory [38], and less neuropatho-165
logical lesions at death [39].166
Interestingly subjects with plasma caffeine level167
greater than 1200 ng/ml at onset were associated with168
stable MCI and no conversion to dementia during the169
2–4 years follow-up examination [35].170
Several studies suggest that adenosine receptors171
change their pattern of localization and density in172
affected brain regions. Postmortem analyses of the173
frontal cortex of AD patients showed that the total174
number and levels of A2AR, but also A1R, are signif-175
icantly increased in either early or advanced stages176
of the disease.177
In particular, the blockade of adenosine A2AR 178
receptors, which have a synaptic localization in the 179
hippocampus [40], prevents A induced amnesia, 180
as well as A2AR antagonists prevent A-induced 181
toxicity in cultured neurons [41]. In addition, 182
oral administration of a selective A2AR antagonist 183
improves spatial memory and reduces tau hyperphos- 184
phorylation in tau mice. These findings support the 185
concept of direct effects of A2AR on neurons to con- 186
trol their susceptibility to neurotoxic stimuli. 187
Alternatively, A2AR might control the apoptotic 188
machinery in neurons and other types of cells in the 189
brain, in a manner similar to the control by A2AR of 190
apoptosis in PC12 cells or in neutrophils [28]. 191
Of interest, there are currently five concurring 192
hypothesis to explain the robust neuroprotective 193
effects afforded by A2AR in noxious brain conditions 194
in adult animals: (1) presynaptic control of glutamate 195
release; (2) control of astroglyosis and of glutamate 196
uptake and release by astrocytes; (3) direct control 197
of neuronal viability by interference with pathways 198
of cell death; (4) control of microglia reactivity; (5) 199
control of the reactivity of infiltrating lymphoid cells 200
[28]. 201
It is now well established that especially dur- 202
ing the earliest phases of AD, inflammation is a 203
predominant event, and that activation of the adeno- 204
sine system through A2AR agonism can lead to the 205
downregulation of the inflammatory response [42] as 206
well as the prevention of A-induced synaptotoxicity 207
by promoting the release of interleukin-10 (IL-10), 208
the major anti-inflammatory cytokine, by resident 209
cells. Another critical aspect pointing to the use of 210
adenosine receptor agonists is that AD patients show 211
impaired signaling by the neurotrophin molecule 212
brain derived neutrophic factor (BDNF), and that 213
A2AR activation is critical for both BDNF-dependent 214
and independent hippocampal synaptic transmission, 215
plasticity, and long term potentiation. Based on the 216
“bidirectional effect” of A2AR activation and inhi- 217
bition proposed by Dai and Zhou [43], different 218
stages of the pathological process as well as the route 219
of administration may significantly impact the effi- 220
cacy of treatment with either agonists or antagonists 221
for adenosine receptors. The apparently paradoxi- 222
cal use of two oppositely acting ligands to treat the 223
same neurodegenerative condition suggests that fac- 224
tors such as dosage, drug delivery method, state of 225
disease progression, and extracellular concentrations 226
of potential excitotoxic transmitters might determine 227
similar cellular responses to opposite pharmacolog- 228
ical treatments. More specifically, it seems that the 229
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protection afforded by A2AR agonists against AD230
is transient but effective during the earliest phases231
of the disease, and it is mainly achieved through232
a stimulatory effect on the release and production233
of anti-inflammatory cytokines by resident glial and234
peripheral immune cells. Conversely, both prophylac-235
tic and long-term neuroprotective effects of caffeine236
and/or A2AR antagonists are for the most attributable237
to inhibition of reactive oxygen species activity, tau238
pathology and A production by neuronal cells [44].239
Moreover, the role of A2AR as a neuromodula-240
tor as well as homeostatic control in the brain to241
integrate dopamine, glutamate and BDNF signaling242
and to modulate synaptic plasticity in brain regions243
relevant to learning and memory, provides the molec-244
ular and cellular bases for A2AR control of cognition245
[45].246
b) Vascular dementia247
In elderly patients there is an increased likelihood248
of other neuropathological abnormalities including249
cerebrovascular lesions [46–48]. Over the last years,250
there has been increasing evidence that the previously251
held sharp distinction between AD and VaD may not252
be so clear-cut, especially in old age [2].253
VaD is the second most common cause of dementia254
after AD. The diagnosis of VaD is based on a number255
of criteria: cognitive deficits, history of stroke and/or256
focal vascular neurological deficits, and temporal257
association between stroke and onset of dementia258
[49]. VaD arises as a consequence of ischemic insults259
such as hemorrhage and hypoperfusion that trigger260
neurodegeneration by depriving nerve cells of oxy-261
gen and glucose [50, 51]. Such deprivation results in262
the depletion of nerve cell energy supplies, leading to263
membrane depolarization, followed by an excessive264
release of glutamate which activates the N-methyl-D-265
aspartate receptor (NMDAR). This allows the influx266
of toxic levels of Ca2+ into nerve cells, which, in turn,267
activates intracellular calcium-dependent enzymes268
[52, 53].269
One of the main adaptive mechanisms in response270
to hypoxia/ischemia is the cellular activation of271
adenosine A1R which inhibits excessive excitatory272
synaptic transmission. On the contrary, adenosine273
A2AR contributes to excessive excitotoxicity.274
A2AR antagonists are protective against ischemic275
damage in different animal model of ischemia admin-276
istered both preischemia and after hypoxia/ischemia.277
This ability is largely attributed to the control of278
excessive glutamatergic transmission and of the ensu-279
ing acute excitoxicity after ischemia [54].280
A further mechanism by which A2AR antago- 281
nism is protective may be due to the capability of 282
increasing GABA extracellular concentration during 283
ischemia. The major part of excitatory glutamater- 284
gic innervation is modulated by inhibitory GABA 285
releasing interneurons. Potentiation of GABAergic 286
synaptic transmission has neuroprotective effects in 287
several experimental models of cerebral ischemia 288
[55] and evidence shows that selective A2AR stim- 289
ulation decreases ischemia-evoked GABA outflow 290
[56, 57] and enhances GABA transport into nerve 291
terminals. 292
Neuroprotective strategies with antagonists of 293
adenosine A2AR are aimed at targeting the brain 294
parenchyma to antagonize excitotoxicity and ensuing 295
production of harmful molecular events responsible 296
for acute brain damage. The limit of such strategies 297
is that these drugs are effective if administered in the 298
first 4 hours after ischemia (in about the same time- 299
window offered by clot removing therapies) [54]. 300
In an apparent paradoxical manner, also adeno- 301
sine A2AR agonists were found protective under 302
hypoxia/ischemia. 303
In the hours and days after ischemia, adenosine 304
A2AR located on vascular and blood cells may be the 305
targets of agonist drugs aimed at dampening vascular 306
adhesion signals and neuroinflammation [54]. 307
Indeed, adenosine acting on A2AR on endothelial 308
cells of brain vessels is implicated in cerebral blood 309
flow regulation as a vasodilator agent, thus adenosine 310
A2AR agonists might favor brain reperfusion after 311
ischemia [58]. 312
Moreover, a bulk of evidences indicates that 313
peripheral effects on A2AR located on blood cells 314
greatly account for protective effects of adenosine 315
A2AR agonists after ischemia. In fact, the A2AR 316
is expressed both on cells of innate (microglia, 317
macrophages, mast cells, monocytes, dendritic cells, 318
neutrophils) and on adaptive (lymphocytes) immu- 319
nity [59]. 320
Finally, A2AR activation is known to reduce 321
ischemia-induced rolling, adhesion, and transmigra- 322
tion of various peripheral inflammatory cells (such as 323
lymphocytes, neutrophils) [59]. 324
c) Idiopathic normal pressure hydrocephalus 325
iNPH may be considered a treatable neurodegener- 326
ative disease, affecting predominately elderly people. 327
It is caused by altered cerebrospinal fluid (CSF) reab- 328
sorption and metabolism affecting brain homeostasis. 329
Increased CSF volume can result in the damage of 330
brain tissue and several brain disturbances. iNPH is 331
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manifested clinically as gait instability, urinary incon-332
tinence, and dementia [60]. It is important to mention333
that iNPH is the reason of about 5% of all dementia334
cases [60].335
The degenerative changes accompanying iNPH336
may be reversible if they are recognized early and337
treated properly. The early diagnosis of iNPH is dif-338
ficult because of various disease manifestations and339
overlap with other neurological disorders, which may340
also present the above-mentioned symptoms com-341
mon in elderly. It could be easily mistaken for other342
neurodegenerative disorders, which makes iNPH one343
of the important misdiagnosed diseases worldwide344
[61, 62].345
The most frequent therapeutic approach to iNPH346
is the ventriculoperitoneal shunt insertion, connect-347
ing the brain ventricles to abdominal cavity, where348
the excessive CSF volume can be absorbed [63, 64].349
CSF shunting can lead to partial or complete amelio-350
ration of the patient’s state with full or partial return351
to premorbid social and health condition. Unfortu-352
nately, the effect of the shunt is not durable. Recent353
data showed that nearly half of the initially well354
treated iNPH patients eventually developed iNPH-355
related dementia within a 4.7 years median follow356
up. iNPH-related degenerative changes of the brain357
appear usually early in the course of the disease,358
stressing the role of timely diagnostics [65]. Diagno-359
sis at the early stage gives patients high probability of360
all symptoms disappearing after shunt insertion [64,361
66].362
It has been hypothesized that cerebrovascular dis-363
eases could have a role in etiology of chronic364
hydrocephalus [67]. Moreover, many studies show a365
significantly increased prevalence of cardiovascular366
diseases and risk factors for vascular diseases in iNPH367
compared to healthy subjects [68]. So far contrasting368
data have been reported on inflammatory involvement369
in iNPH patients. Some studies suggest an alteration370
of immune system in this pathology [69], but other371
authors deny it [70].372
Since Ado system plays an important role373
both in vascular protection and in modulation of374
inflammatory reactions and neuroinflammation, it375
could be involved in the pathophysiology of iNPH376
disease.377
It is interesting to note that the levels of many378
inflammatory molecules are different in iNPH379
than healthy subjects. Altered CSF levels of IL-380
4 and IL-10 [69], transforming growth factor381
(TGF)–1, TGF- type II receptor, leucine-rich -2-382
glycoprotein [70], monocyte chemotactic protein-1383
[69] and tumor necrosis factor- were reported in 384
iNPH patients. 385
In particular, elevated levels of CSF IL-10 were 386
found in patients with iNPH [71], contrasting pub- 387
lished lower levels in AD [72]. 388
IL-10 level decreases after shunt insertion and 389
stabilizes at levels lower than 0.5 pg/ml for two years 390
[71]. 391
Interestingly, activation of A2AR on both glial cells 392
[73] and neurons [74] has been shown to increase 393
IL-10 production. 394
PERIPHERAL CELLS TO STUDY BRAIN 395
DISORDERS 396
Nowadays we need to find a reliable, minimally 397
invasive, and inexpensive biomarker for dementia. 398
Given the limited availability of brain tissue, we need 399
to find putative dementia biomarkers and genetic risk 400
alleles from blood tests and CSF samples [75, 76]. 401
In particular peripheral blood mononuclear cells 402
(PBMCs) reflect inflammatory mechanisms in a 403
more specific way compared to the serum/plasma 404
since these blood cells are a critical component of 405
the immune system which provide defense against 406
infection and respond to intruders. The lymphocyte 407
population consists of CD4+ and CD8+ T cells, 408
B cells and natural killer cells, CD14+ monocytes, 409
basophils, neutrophils, eosinophils, and dendritic 410
cells. PBMCs offer the advantage to study the molec- 411
ular events associated with dementia development 412
in the different stages of the disease, while stud- 413
ies on post-mortem brain samples offer a picture 414
of the end results of these processes, which do not 415
necessarily reflect the mechanisms underlying dis- 416
ease development. Moreover, PBMCs share much of 417
the non-synaptic biochemical environment of neu- 418
rons and contain the full complement of epigenetic 419
enzymes and machinery, which are found in both neu- 420
rons and peripheral nucleated cells, as in most other 421
tissues. 422
Several differences have been shown in PBMCs 423
from patients affected by dementia compared to 424
sex- and age-matched PBMCs from normal indi- 425
viduals. The differences include immunophenotype 426
combined with pro-inflammatory cytokine produc- 427
tion [77], transcriptional and epigenetic mechanisms 428
[78, 79], and global DNA methylation [80]. These 429
substantial evidences are in favor of the notion that 430
PBMCs seem to directly participate to neuropatho- 431
logical processes and provide a window into the 432
central nervous system [76]. 433
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A2AR IN PBMCS FROM PATIENTS WITH434
DIFFERENT BRAIN DISEASES435
In light of these considerations, our group has436
investigated the A2AR pathway in PBMCs of AD,437
VaD, iNPH, and mild cognitive impairment (MCI),438
a stage in which patients have a greater cognitive439
decline than expected for their age and educational440
level [81]. MCI could be amnestic (aMCI), con-441
sidered the preclinical state of AD, and multiple442
cognitive domain (mcdMCI) types.443
Indeed, we analyzed the gene expression and444
receptor density of A2AR in PBMCs from above men-445
tioned patients comparing to non-demented age- and446
gender-matched healthy controls with similar educa-447
tional levels.448
Interestingly, in PBMCs we found a significant lin-449
ear increase in A2AR gene expression from iNPH,450
which showed the lowest values, to aMCI, which451
showed the highest values. Similarly, protein density452
was lower in mcdMCI, VaD, and iNPH than controls453
while a similar density was showed in aMCI, AD,454
and controls.455
The lack of a strict correlation between mRNA lev-456
els and receptor densities could be due to the fact that457
we measured the steady state level of A2AR mRNA458
as well as the steady state level of receptor densities.459
We did not take into consideration the mechanisms460
that regulate these processes.461
There could be some miRNAs-dependent mech-462
anisms that could lead to a reduction of the463
translational levels of mRNAs [82]. At post-464
translational level the discrepancy observed between465
gene and protein expression could be explained466
by a quick protein degradation, preceded by some467
post-translational modifications, in order to have a468
transitory effect in response to a certain stimulus [83].469
Moreover, A2AR is upregulated in the preclinical470
stage and in overt AD than controls. In particu-471
lar we found higher A2AR levels in aMCI than472
AD supporting an involvement of the Ado system473
mainly in the early stages of this disease. These474
results seem to fit in with a previous demonstra-475
tion that the increased expressions of A2AR in the476
brain cortex are mainly an early event in AD [84].477
In aMCI, the highest A2AR levels could counterbal-478
ance the existing inflammation. Indeed, the activation479
of A2AR by agonists can lead to the downregulation480
of the inflammatory response [42], to reduce produc-481
tion of pro-inflammatory cytokines and chemokines482
and to increase production of the anti-inflammatory483
cytokines [85].484
We also showed that A2AR expression is lower in 485
VaD, mcdMCI, and in particular in iNPH than con- 486
trols [19, 20]. This downregulation of A2AR may 487
depend on the brain vascular alterations occurred in 488
VaD and iNPH patients [20]. Indeed, the inhibition of 489
A2AR by antagonists is protective against ischemic 490
damage in different animal model of ischemia 491
[54] and decreases infarct volumes after cerebral 492
ischemia [86–90]. However, contrasting data have 493
been reported so far on the beneficial/detrimental 494
effects of A2AR on brain cells, indeed also the ago- 495
nists of A2AR can protect the central nervous system 496
against ischemia [17, 91]. 497
Ultimately determining A2AR expression in 498
PBMCs could contribute to the recognition of cases 499
of aMCI among the heterogeneous group of MCI 500
patients [18] and to the identification of VaD patients 501
with moderate degree of sensitivity and specificity 502
from a heterogeneous group composed of VaD and 503
AD patients. 504
These results highlight the possible role of A2AR in 505
differentiating a particular preclinical state of demen- 506
tia and in distinguishing AD and VaD pathologies that 507
are often closely associated in the elderly [19]. 508
It can be concluded that A2AR may play an impor- 509
tant and distinctive role in the onset of dementia in 510
the elderly especially if similar differences will be 511
confirmed in other neurological diseases. 512
Considering that there are already drugs active 513
on adenosine receptors both in use in clinical prac- 514
tice and under development, we could speculate that 515
A2AR may be a suitable target to study novel com- 516
pounds with higher selectivity, oral bioavailability, 517
stability in vivo, longer half-life, and better capability 518
to cross the blood-brain barrier. 519
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